Abstract
On the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Colorectal Neoplasms / diagnosis
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / genetics*
-
Drug Resistance, Neoplasm*
-
Humans
-
Mutation / genetics*
-
Prognosis
-
Proto-Oncogene Proteins / genetics*
-
Proto-Oncogene Proteins p21(ras)
-
ras Proteins / genetics*
Substances
-
Antineoplastic Agents
-
KRAS protein, human
-
Proto-Oncogene Proteins
-
Proto-Oncogene Proteins p21(ras)
-
ras Proteins